CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate

Study conducted in Peru and Panama

30-Sep-2020 - Germany

CureVac N.V. announced that the first participant has been dosed in a Phase 2a clinical trial of its Covid-19 vaccine candidate, CVnCoV. The dose-confirmation study, entitled CV-NCOV-002, is being conducted in Peru and Panama and will enroll a total of 690 healthy participants in two distinct groups: older adults ages 61 and above, and younger participants 18 to 60 years old.

pixabay.com

Symbolic image

The participants will receive two vaccinations at intervals of 28 days. Different dose levels will be investigated, starting at 6 µg, with the aims to confirm safety and evaluate reactogenicity of the vaccine in older adults. In addition, in a geographical environment with a high incidence of COVID-19 infection, the humoral immune response after administration of CVnCoV will be assessed and the safety database will be expanded to prepare for the start of a phase 2b/3 study. First comprehensive data of Phase 2a in older adults are expected later in the fourth quarter 2020.

The study design was coordinated with and approved by the health authorities and ethics committees of Peru and Panama and is based on preliminary safety and immunogenicity data from CureVac’s ongoing Phase 1 CV-NCOV-001 study in healthy adult volunteers in Germany and Belgium. Pending further data from the ongoing Phase 1 and the Phase 2a study, CureVac plans to initiate the global Phase 2b/3 clinical trial enrolling approximately 30,000 participants in the fourth quarter of 2020.

“The start of the clinical Phase 2a trial in Peru and Panama represents an important step forward in our COVID-19 clinical study program,” Dr. Mariola Fotin-Mleczek, Chief Technology Officer of CureVac, said. “This trial is designed to further confirm the selection of the dose of our vaccine candidate and to confirm that we can provide a safe and tolerable vaccine, also to older adults, who are at a higher risk of experiencing serious impacts from COVID-19.”

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery - Combining Dynamic Biosensors’ Innovative Technologies with Bruker’s High-Performance SPR Portfolio to Establish a Leading Biosensors Business

Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery - Combining Dynamic Biosensors’ Innovative Technologies with Bruker’s High-Performance SPR Portfolio to Establish a Leading Biosensors Business

Novartis restructures of global collaboration with Schering-Plough for fixed-dose combination respiratory therapies - Novartis assumes exclusive worldwide development and marketing rights for investigational once-daily QMF149 being developed for COPD and asthma

Genetic Research: The New Battleground in the Fight Against Heart Disease - University of Ottawa Heart Institute Leads a New Scientific Focus on Preventive Medicine Aimed at Eliminating Heart Disease

BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis - Milestone triggers $10 million payment from Eli Lilly and Company

Agensys and Merck Announce Agreement to Co-Develop and Commercialize a Novel Antibody for Cancer Therapy

Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH - Braunschweig, Germany

Algeta signs €560 million global agreement with Bayer for development and commercialization of Alpharadin for bone metastases

QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments

QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments

European Medicines Agency update on Diane 35 and generics used in the treatment of acne

Gründer­fonds Münster­land and HTGF II In­vest in Cysal GmbH